Last reviewed · How we verify
Vaprisol In 5% Dextrose In Plastic Container (CONIVAPTAN)
Conivaptan, marketed as Vaprisol, is a vasopressin receptor antagonist developed by Cumberland Pharms. It targets the vasopressin V2 receptor to treat hyponatremia, a condition characterized by low sodium levels in the blood. Conivaptan is a small molecule modality with a half-life of 6.7 hours and bioavailability of 42%. As an off-patent medication, it is no longer protected by active patents, allowing generic manufacturers to produce the drug. Conivaptan is administered via a 5% dextrose solution in a plastic container.
At a glance
| Generic name | CONIVAPTAN |
|---|---|
| Sponsor | Cumberland |
| Drug class | Vasopressin Receptor Antagonist |
| Target | Vasopressin V2 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 2005 |
Approved indications
- Hyponatremia
Common side effects
Drug interactions
- CYP3A4 Substrates
- CYP3A4 Substrates
- alfentanil
- alfuzosin
- boceprevir
- fentanyl
- indinavir
- itraconazole
- ketoconazole
- lovastatin
- mibefradil
- nefazodone
Key clinical trials
- Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients (PHASE4)
- Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study (PHASE1)
- Study of Stroke Related Edema Treatments (PHASE2)
- A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia (PHASE3)
- Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients (PHASE4)
- Safety and Efficacy of Conivaptan for the Correction of Hyponatremia in Neurological Patients (PHASE3)
- Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia (PHASE3)
- Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaprisol In 5% Dextrose In Plastic Container CI brief — competitive landscape report
- Vaprisol In 5% Dextrose In Plastic Container updates RSS · CI watch RSS
- Cumberland portfolio CI